deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT01718938

Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase 2 Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis

Sponsor: Alfasigma S.p.A.

Conditions Gastroparesis
Interventions placebo velusetrag dose 1 velusetrag dose 2 velusetrag dose 3
Updated 9 times since 2017 Last updated: Feb 22, 2018 Started: Dec 31, 2012 Primary completion: Dec 31, 2013 Completion: Feb 28, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Gastroparesis, this trial is completed. The trial is conducted by Alfasigma S.p.A. and has accumulated 9 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshotCompleted~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshotCompleted~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshotCompleted~Oct 2018 – ~Jan 2021 · 27 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

  5. Oct 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Jun 2018 — Oct 2018 [monthly]

    Completed PHASE2

  2. Feb 2018 — Jun 2018 [monthly]

    Completed PHASE2

  3. Feb 2017 — Feb 2018 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alfasigma S.p.A.
  • Theravance Biopharma
Data source: Theravance Biopharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations